Article
Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease.
Therapeutic drug monitoring - 1 Aug 1996
Shiffman M L, Luketic V A, Sanyal A J, Thompson E B
Abstract excerpt
Lidocaine is converted to its primary metabolic product monoethylglycinexylodide (MEGX) via cytochrome P-4503A4 within the liver. A steady-state concentration of MEGX appears in serum within 15 min following the intravenous administration of lidocaine. The present article reviews some of the data suggesting that this MEGX value can be utilized to assess hepatic function. MEGX production declines stepwise with the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.